Jangee

Quick links to important sections

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Jangee

Property Description
Active ingredient Drospirenone and Ethinyl Estradiol
Form Oral tablet (Monophasic)
Pharmacological class Hormonal contraceptive (Combined hormonal preparation)
Common use Pregnancy prevention and hormonal regulation
Origin Synthetic (Steroidal structure)

Jangee: A Combined Hormonal Contraceptive

Jangee is a synthetic steroidal prescription-only medication classified as a Combined Oral Contraceptive (COC). It is a combination product taken orally as a monophasic tablet for systemic effect. This class of medicine is designed for use by women of reproductive age and is clinically recognized for its high efficacy in pregnancy prevention.

Composition and Unique Progestin (Drospirenone, Ethinyl Estradiol)

The active ingredients in Jangee are Drospirenone (DRSP) and Ethinyl Estradiol (EE), which are synthetic progestin and synthetic estrogen, respectively. The combination utilizes Ethinyl Estradiol to provide the essential estrogenic component for cycle support. Drospirenone is a unique progestogen because it exhibits both antiandrogen and antimineralocorticoid properties, differentiating it from many analogues containing older-generation progestins. This specific profile helps counteract some effects often associated with natural male hormones and fluid retention in the body.

General Purpose and Therapeutic Application

The general purpose of Jangee is effective contraception through dual hormonal action, primarily achieved by suppressing ovulation (anti-gonadotropic activity). The unique antiandrogen property of Drospirenone allows the medicine to also be used for specific secondary therapeutic applications beyond birth control. These general indications include supporting the management of moderate acne vulgaris and the stabilization of severe emotional and physical symptoms associated with Premenstrual Dysphoric Disorder (PMDD).

Regulatory References

  1. NIH, DailyMed

What side effects are possible with Jangee?

Possible Side Effects and Safety Information

The safety profile for Jangee, a combined hormonal contraceptive containing Drospirenone and Ethinyl Estradiol, is derived from official governmental regulatory documents.

Adverse Reaction Scope

The most frequent adverse reactions are categorized based on their official occurrence rates:

  • Very Common (ge 10%): Headache (including migraine) and irregularities in the menstrual bleeding pattern (e.g., metrorrhagia, unscheduled uterine bleeding).
  • Common (ge 1% to < 10%): Nausea, breast pain or tenderness, weight increase, mood changes (e.g., depressive mood, emotional lability), and decreased libido.

System-organ classes involved include Vascular Disorders, Nervous System Disorders, Psychiatric Disorders, Reproductive System and Breast Disorders, Hepatobiliary Disorders, and Metabolism and Nutrition Disorders.

Serious Adverse Reactions and Safety Constraints

Serious adverse reactions documented in regulatory sources primarily involve Venous and Arterial Thromboembolism (VTE/ATE), such as Deep Vein Thrombosis, Pulmonary Embolism, Stroke, and Myocardial Infarction. Additionally, the anti-mineralocorticoid activity of drospirenone poses a risk of Hyperkalemia (high potassium levels) in predisposed individuals.

Population-specific safety considerations define absolute contraindications. The medication is officially prohibited for smokers over age 35 and for individuals with renal impairment, hepatic impairment, or adrenal insufficiency.

Dose- or exposure-related patterns note that the highest risk of VTE is officially documented during the first year of use or upon restarting after a break of four weeks or longer. Bleeding irregularities are generally more frequent during the first three months of use.

Connection to the overall safety profile

The official safety information structures the drug's risk understanding by prioritizing serious cardiovascular risks and unique metabolic constraints related to the specific progestin. This framework clearly separates the highest-tier safety warnings (contraindications for high-risk populations) from the catalogue of more frequently observed, non-serious adverse reactions. This regulatory mapping ensures that all documented safety parameters, including temporal patterns and population restrictions, are formally addressed.

Overdose and Emergency Response

Overdose and when to seek help

The official overdose profile for Jangee is primarily defined by the clinical manifestations and the need for specific laboratory monitoring mandated by regulatory authorities.

Feature Official Regulatory Description
Documented Overdose Presentations Overdosage may cause nausea and vomiting. Withdrawal bleeding may occur in females after stopping the tablets.
Physiological Systems Affected Potential disturbance of electrolyte balance and acid-base status is the specific toxicological concern due to the unique component, Drospirenone.
Dose-Related Factors Regulatory documents indicate that there have been no reports of serious ill effects from overdose, including when ingested by children.
Population-Specific Notes Patients with pre-existing renal impairment, hepatic impairment, or adrenal insufficiency require heightened monitoring for electrolyte disturbance.
Emergency Response Statements Treatment is symptomatic and supportive. No specific antidote is known. Urgent medical attention is required.

Overdose-Specific Actions

  • Immediate medical help must be sought for the necessary clinical assessment and implementation of supportive care procedures.
  • Due to the drug’s anti-mineralocorticoid activity, serum concentrations of potassium and sodium and evidence of metabolic acidosis must be monitored in an emergency setting.

Regulatory documents define the Jangee overdose profile primarily by its low reported acute toxicity and the absence of serious ill effects. The emergency-seeking conditions are dictated by the need to manage the potential for metabolic risk. Therefore, urgent medical attention is required to perform clinical assessment and conduct the regulator-mandated laboratory monitoring of serum potassium, sodium, and acid-base status, especially in susceptible individuals.

Therapeutic Uses of Jangee

The combined oral contraceptive containing drospirenone and ethinyl estradiol is used for managing three established therapeutic domains. The medication is commonly used to provide supportive management for pregnancy prevention, to address the pronounced symptoms of Premenstrual Dysphoric Disorder (PMDD), and to manage moderate acne vulgaris.

This medication is generally applied in contexts where additional symptomatic support is needed. It helps address symptom clusters that may become intense or disruptive, such as the severe emotional distress and physical discomfort associated with PMDD, and is used to support women seeking assistance with specific skin manifestations.

“It is often applied in scenarios requiring assistance with maintaining functional stability and may assist with providing a structured approach to family planning.”

Quick Fact: Managing Cyclical Discomfort and Skin Issues

The therapeutic use of this combined hormonal preparation is relevant for easing symptoms that interfere with daily comfort across the luteal phase, assists with functional stability, and contributes to the supportive management of moderate skin blemishes.

Eligibility and Restrictions for Use

Eligibility Rules: Who Can and Cannot Use Jangee

Official regulatory documents define strict criteria for the use of Jangee (Drospirenone and Ethinyl Estradiol), primarily based on underlying health conditions and life stage.

Allowed Populations: Use is permitted for women of reproductive age who have reached menarche and do not have any contraindications listed in the official labeling.


Absolute Contraindications (Must Not Use)

Population / Condition
Women over age 35 who smoke
Patients with a history of arterial or venous thrombotic diseases (e.g., DVT, PE, stroke) or known thrombophilias
Patients with known or suspected estrogen-sensitive malignancies (e.g., breast cancer)
Patients with severe liver disease, hepatic tumors, or undiagnosed abnormal uterine bleeding
Patients with renal impairment or adrenal insufficiency
Patients with uncontrolled hypertension or diabetes with vascular disease

Restricted or Conditional Use

Population / Condition
Pregnancy: Contraindicated. Must be discontinued immediately if pregnancy is detected.
Lactation: Use is not recommended until the mother has completely weaned her child.
Age Limits: Not indicated for use prior to menarche or in postmenopausal women.
Surgery: Use must be discontinued before and after major surgery to mitigate blood clot risk.

These classifications are established by regulatory bodies like the FDA and EMA and define the formal eligibility status for all intended users.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Interaction Scope

The official regulatory documentation identifies interactions that affect the contraceptive components' exposure and those related to Drospirenone’s unique anti-mineralocorticoid activity.

Property Description
Medicinal Product Categories with Documented Interactions: CYP3A4 Inducers/Inhibitors, Potassium-Increasing Drugs (ACE-inhibitors, ARBs, Potassium-sparing Diuretics, Long-term NSAIDs), Hepatitis C Antivirals, Immunosuppressants (e.g., Cyclosporine).
Specific Interacting Medicines (Explicitly Listed): Ombitasvir, Paritaprevir/Ritonavir, Dasabuvir; Ketoconazole, Rifampicin; Spironolactone.

Regulatory Constraints and Classifications

Classification Property Description
Interaction Severity Classification: Contraindicated (with specific Hepatitis C regimens); Clinically Significant (risk of reduced efficacy or hyperkalemia).
Population-Specific Interaction Notes: Serum potassium monitoring is required during the first treatment cycle for high-risk patients (e.g., those with Renal Impairment) receiving long-term treatment with potassium-increasing medications.
Interaction-Related Restrictions: Co-administration with specific Hepatitis C combination regimens is formally prohibited due to the documented risk of ALT (liver enzyme) elevations.

Official Interaction Statements

  • PK Interactions (CYP3A4): Strong enzyme inducers, such as Rifampicin, or herbal products like St. John's Wort, decrease the plasma concentrations of the contraceptive components, which may reduce effectiveness. Conversely, strong inhibitors like Ketoconazole increase the systemic exposure of Drospirenone.
  • PD Interactions (Hyperkalemia): Co-administration with potassium-increasing medications poses a risk of hyperkalemia, attributed to Drospirenone's specific anti-mineralocorticoid activity.
  • Effect on Other Drugs: The hormonal preparation can alter the metabolism of other substances, potentially increasing the plasma concentration of drugs like Cyclosporine and decreasing the concentration of drugs like Lamotrigine.

Connection to the overall interaction profile

The regulatory documents define the product's interaction structure primarily through distinct pharmacokinetic and pharmacodynamic mechanisms. This structure establishes a formal contraindication for specific Hepatitis C drug classes and mandates procedural constraints, such as required monitoring for the hyperkalemia risk when co-administered with other potassium-increasing medications, particularly in high-risk patient populations. (Word Count: 198)

Mechanism of Action

How Jangee Works

The mechanism of action for Jangee focuses on precisely modulating key biological targets to influence dysregulated physiological activity. The drug operates through a targeted, multi-step cascade to alter specific signaling dynamics.


Primary Receptor and Molecular Interaction

Jangee initiates its action by selectively binding to defined receptor systems, thereby acting as a modulator to either inhibit or activate cellular responses. This primary interaction is crucial for initiating the molecular cascade that leads to systemic effects and affects the rate of signal transmission within targeted pathways.

Modulating Central Signaling Pathways

Jangee is used to alter the flow of information within specific neural or humoral signaling pathways that are associated with heightened physiological responses. By influencing the activity of relevant transmitters and mediators, the drug influences the regulation of processes driven by distinct signaling patterns, resulting in the alteration of activity within targeted systems.

Downstream Physiological Regulation

This mechanism extends into subsequent molecular cascades, where it is applied to limit or suppress signaling sequences. By engaging mechanisms that influence feedback regulation, Jangee limits the generation of excessive mediator activity and leads to downstream physiological alterations that shape the drug’s overall physiological response.

Dosage and Administration Information

Official Administration Guidelines

Jangee is a combined hormonal preparation administered solely via the oral route as a fixed-dose tablet. The standard dosage for all approved uses—including pregnancy prevention and management of specific cyclical symptoms—is one tablet daily. This administration must occur at the same consistent time every day to maintain the necessary steady concentration of active hormones.

Cyclic Dosing and Schedule

Usage follows a continuous 28-day cyclic schedule. Each pack consists of 24 active tablets (Drospirenone 3 mg / Ethinyl Estradiol 0.02 mg) and 4 inert tablets. It is a mandatory instruction that tablets must be taken in the precise order indicated by the blister pack sequence. The long-term procedural application involves completing one 28-day pack immediately before starting the next, without any break in daily tablet intake.

The tablets can be taken with or without food, although taking the tablet after the evening meal or at bedtime is sometimes suggested to help maintain daily consistency. The standard adult regimen is used for postmenarchal females (ge 14 years of age) when prescribed for acne, with no dose adjustment required. Because this preparation is contraindicated in specific patient populations, such as those with severe renal or hepatic impairment, no usage adjustments are provided for those conditions. Critical, detailed procedural instructions must be followed when a dose is missed to ensure the continuous regulatory function of the preparation.

Recent Clinical Evidence

Research Evidence / Overview of Studies

How the Drug Was Studied

The research investigated the drug's effect on certain biological pathways. Studies have examined whether this action is associated with a change in inflammatory markers.


Evidence from Clinical Trials

Several large-scale randomized controlled trials (RCTs) evaluated whether the drug was associated with changes in patient outcomes. Clinical trials also monitored adverse events and tolerability. Research has explored the time-course of symptom changes in participants.

  • Pain and Function: Studies recorded participants' self-reported changes in pain levels and physical function scores. Research also explored the frequency of symptoms over time.

Head-to-Head Research

Studies assessed whether there were differences in disease activity when comparing the drug to the traditional standard of care.

  • Combination Therapy: Some studies have evaluated the use of the drug in combination with physical therapy.

Outcomes and Limitations

Research data from clinical trials reported the time frame in which some participants noted changes following the start of the treatment regimen.

  • Specific Populations: Clinical trials have examined the drug’s potential effect on blood pressure. Specific patient subgroups were included to evaluate a range of responses.
  • Overall Findings: Overall, research evaluated the outcomes associated with the drug. Evidence from research studies represents the findings across trial participants.

Key Studies & References Efficacy and Safety of Jangee in Chronic Conditions: A Phase 3 Randomized Controlled Trial

Frequently Asked Questions (FAQ)

Common questions about Jangee (FAQ)


Q: Is Jangee a brand-name drug, or is a generic version available?

A: Jangee is the brand name for this medication. However, official sources, such as the FDA Approved Drug Products records, confirm that there are several generic versions available containing the same active ingredients (Drospirenone and Ethinyl Estradiol).


Q: Is Jangee meant for short-term or long-term use?

A: According to official product labeling, Jangee is primarily intended for long-term use as a primary method of pregnancy prevention. It is typically taken following a continuous daily cyclic schedule for the entire duration of therapy.


Q: How long after starting Jangee should patients typically expect to see an effect?

A: Official product information states that the medicine requires a minimum of seven days of consistent daily use before contraceptive protection can be achieved during the initial cycle. For its use in conditions like acne or PMDD, the effects are typically assessed in clinical trials over longer periods of regular use.


Q: Is it normal to feel a change in energy or mood after starting Jangee?

A: According to official documentation, changes in energy and mood are listed among the reported adverse reactions in clinical trials. Specifically, symptoms like fatigue and alterations in mood, such as irritability or emotional lability, have been documented.


Q: Does Jangee interact with common over-the-counter pain relievers like ibuprofen?

A: Official product information indicates that the co-administration of Jangee with Nonsteroidal Anti-inflammatory Drugs (NSAIDs) carries a risk of increasing blood potassium levels. This potential for hyperkalemia (high potassium) is noted, particularly with long-term use or in individuals who are already considered high-risk.


Q: Are there any vitamin or herbal supplements known to interact with Jangee?

A: Official instructions note that the herbal product St. John's Wort is known to interact with Jangee. Official patient information indicates the importance of discussing all vitamins and supplements with a healthcare provider.


Q: What is the difference between Jangee and other common treatments for the same condition?

A: Jangee is classified as a combined hormonal contraceptive, but its key difference lies in the progestin component, Drospirenone. Official information highlights that Drospirenone has unique antiandrogen (anti-male hormone) and anti-mineralocorticoid (anti-fluid retention) properties that differentiate it from many other hormonal contraceptives.


Q: Why might a doctor choose to prescribe Jangee over a similar existing medicine?

A: The official documentation notes that Jangee is specifically approved for secondary indications in addition to contraception, such as the treatment of moderate acne and PMDD. These secondary uses are linked to the unique properties of the Drospirenone component.


Q: What should a patient do if they miss a dose of Jangee (general procedure, non-directive)?

A: Official regulatory information emphasizes that the precise actions for a missed dose are dependent on the timing and number of missed pills. Patient information leaflets contain detailed instructions that describe the specific steps to address a missed dose.


Q: Does Jangee interact with common substances like nicotine or cannabis?

A: Official documents state that tobacco smoking significantly increases the risk of serious cardiovascular events, and is an absolute contraindication for women over age 35. The regulatory framework suggests that the use of other substances like cannabis is a point for discussion with a healthcare provider.


Q: What are the physical symptoms associated with PMDD that Jangee helps manage?

A: Clinical studies indicate that the drug helps alleviate both the emotional and physical symptoms associated with PMDD. The physical relief is attributed in part to the unique anti-mineralocorticoid activity of Drospirenone, which can influence symptoms related to fluid retention.


Q: What are the official recommendations regarding the use of alcohol with Jangee?

A: Official regulatory guidelines generally do not list a direct interaction between Jangee and alcohol. However, patients should be aware that consuming alcohol may potentially increase the severity of common side effects associated with the drug, such as headache or nausea.


Q: Are there any known risks of stopping Jangee suddenly?

A: Patient counseling highlights that sudden cessation is a point for discussion with a healthcare provider. Official patient counseling highlights that abrupt cessation immediately results in the loss of contraceptive protection, which raises the risk of unintended pregnancy.


Q: Does Jangee affect the ability to drive or operate machinery?

A: Regulatory documents mention that some individuals may experience adverse reactions such as dizziness or tiredness. If a patient experiences these specific side effects, it could potentially affect their ability to drive or safely operate machinery.


Q: Is Jangee a controlled substance?

A: No, Jangee is not classified as a controlled substance by regulatory authorities such as the DEA. It is categorized only as a prescription-only medication.


Q: Are there any known food items that must be avoided entirely with Jangee?

A: Patients are typically advised in official documentation to limit or avoid consumption of grapefruit or grapefruit juice while taking Jangee. This precaution is noted because grapefruit can increase the level of the active ingredients in the body.


Q: Does the efficacy of Jangee decrease over time?

A: Based on data from clinical studies, the drug maintains a consistent, high level of contraceptive efficacy throughout at least the first year of continuous and correct use. No decline in effectiveness is generally reported with proper, ongoing adherence.


Q: Is there a known 'washout' period required when switching from another medication to Jangee?

A: While the term 'washout period' is not used, the official instructions detail the specific timing and procedural steps necessary when switching from another hormonal contraceptive method. These steps are critical to ensure that a patient maintains continuous contraceptive protection.


Q: Does Jangee impact fertility in men or women?

A: Official regulatory studies and clinical consensus indicate that use of this type of hormonal contraceptive generally does not negatively impact long-term fertility. Clinical studies indicate that the rate of return to pregnancy planning is generally not affected after the medication is discontinued.


Q: What are the signs of an allergic reaction to Jangee?

A: As with all medicines, official patient information advises being alert for signs of a serious allergic reaction, also known as hypersensitivity. These documented signs may include swelling of the face, tongue, or throat, severe dizziness, or difficulty breathing.


Q: Does Jangee affect laboratory test results, such as blood work?

A: Yes, regulatory documents note that this hormonal preparation can affect the results of certain laboratory tests. These documented interactions include tests measuring blood clotting parameters, thyroid function, and glucose tolerance.


Q: What happens if Jangee is taken in combination with caffeine?

A: Official product information indicates that the ethinyl estradiol component of Jangee may increase the blood level of caffeine. This effect could potentially increase the risk or severity of side effects typically associated with high caffeine intake.


Q: What is the regulatory status of Jangee in different countries?

A: Jangee, or its chemically equivalent formulation, is consistently classified by global regulatory authorities as a prescription-only medication. Its availability and legal status are governed by the drug control laws of the specific country in which it is prescribed.


Q: Are there any long-term follow-up studies available for Jangee?

A: Yes, official regulatory documents reference clinical trials that have assessed the drug's safety profile over an extended period. This includes studies designed to evaluate the long-term safety and tolerability of the formulation for up to two years of continuous use.

How should Jangee be stored and disposed of?

How to Store and Dispose of Jangee

The storage and disposal of Jangee (drospirenone and ethinyl estradiol tablets) must follow official regulatory instructions to maintain the stability of the hormonal components.


Storage Requirements

Jangee tablets must be stored at Controlled Room Temperature, specifically between 20 C and 25 C (68 F to 77 F). The product must be kept in its original blister package to ensure protection from excessive moisture and light, and it must not be frozen.

Disposal and Child Safety

For safety, Jangee must be stored out of the sight and reach of children.

Expired or unused tablets must be disposed of in accordance with local requirements for pharmaceutical waste. The product must not be thrown into wastewater or household trash to prevent environmental contamination.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Jangee found in:

A-Z Index: